Evidence map›Paper›PMID 36309984›Full record

Trial reportNephrology (Carlton, Vic.)2023

Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review.

Benjamin Talbot, Alan Cass, Robert Walker, Lai Hooi, Meg Jardine, Min Jun, Kris Rogers, Louisa Sukkar, Brendan Smyth, Martin Gallagher

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nephrology (Carlton, Vic.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benjamin TalbotThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7029-7813
Alan CassMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Robert WalkerDunedin School of Medicine, University of Otago, Dunedin, Otago, New Zealand.ORCID https://orcid.org/0000-0003-3366-0956
Lai HooiSultanah Aminah Hospital, Johor Bahru, Johor, Malaysia.ORCID https://orcid.org/0000-0002-4628-3806
Meg JardineThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.
Min JunThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.
Kris RogersThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5497-4298
Louisa SukkarThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.
Brendan SmythThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-1838-3348
Martin GallagherThe George Institute for Global Health, The University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9187-6187

Funding

National Health and Medical Research Council 2011/GNT1030973
6 · The paper itself

Abstract

aimThis study examined whether survival and causes of death differed between participants enrolled from Australia (AUS), Malaysia (MYL), and New Zealand (NZ) in extended follow-up of the Study of Heart and Renal Protection (SHARP), a randomized controlled trial (RCT) of participants with moderate to severe chronic kidney disease comparing placebo to combination therapy with Simvastatin and Ezetimibe.

methodsAll participants alive at final SHARP study visit in participating centres were eligible for inclusion. Consenting participants were re-enrolled following final SHARP Study visit and followed for 5 years. Data collection included: significant medical events, hospital admissions and requirement for kidney replacement therapy. Data linkage was performed to national kidney and mortality registries. The primary outcome was all-cause mortality compared across the three countries.

resultsThe SHARP trial randomized 2029 participants from AUS (1043/2029, 51%), MYL (701/2029, 35%), and NZ (285/2029, 14%), with 1136 participants alive and eligible for extended follow-up at the end of SHARP. In multivariable analysis, risk of death was increased for participants in MYL (HR 1.37, 95% CI 1.17-1.61, p < .001) and NZ (HR 1.28, 95% CI 1.04-1.57, p = .02) when compared to AUS participants. Adjustment for kidney transplantation as a competing risk did not explain the variation seen between countries.

conclusionThis study allows a better understanding of the differences in long-term mortality risk across participants from AUS, MYL, and NZ in extended follow-up of the SHARP study and demonstrates the feasibility and value of extended follow-up of participants enrolled in RCTs.

Indexed as

Kidney TransplantationRenal Insufficiency, ChronicEzetimibeHumansKidneySimvastatinEzetimibeSimvastatincardiovascular diseasechronic kidney diseaseextended follow-upinternational comparisonmortality

Identifiers

PMID36309984
PMCPMC10946510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.